HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience

Erythropoiesis-stimulating agents, such as recombinant human erythropoietin, are commonly used for the treatment of anemia in patients with chronic kidney disease (CKD). In 2007, HX575 (Binocrit(®)) became the first biosimilar epoetin alfa to be approved by the European Medicines Agency (EMA). The d...

Descripción completa

Detalles Bibliográficos
Autores principales: Dellanna, Frank, Goldsmith, David, Krendyukov, Andriy, Seidl, Andreas, Höbel, Nadja, Combe, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739117/
https://www.ncbi.nlm.nih.gov/pubmed/29296077
http://dx.doi.org/10.2147/DDDT.S146147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739117/
https://www.ncbi.nlm.nih.gov/pubmed/29296077
http://dx.doi.org/10.2147/DDDT.S146147

Ejemplares similares